Summary
Preparations of human leukocyte (α) and fibroblast (β) interferon were given intramuscularly to rabbits and monkeys, and circulating interferon was measured. In rabbits, but not in monkeys, a marked difference between the two interferons was noted in that higher titers of circulating antiviral activity were obtained with leukocyte than with fibroblast interferon. In mice, injected interperitoneally, a similar difference could be noted. However, levels of antiviral activity in homogenates of spleens and lungs did not differ between mice injected with either interferon.
Fibroblast interferon that was injected intrathecally in monkeys was found to diffuse throughout the cerebrospinal canal and to reach the serum compartment. Some interferon could also be recovered from the pia mater surrounding the brain hemispheres, but none was found in the deeper layers of the brain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Billiau, A., de Somer, P.: Clinical use of interferons in viral infections. In:Stringfellow, D. A. (ed.), Interferon and Interferon Inducers, Clinical Applications, 113–144. New York-Basel: Marcel Dekker 1980.
Billiau, A., de Somer, P., Edy, V. G., de Clercq, E., Heremans, H.: Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans. Antimicrob. Agents Chemother.16, 53–63 (1979).
Billiau, A., van Damme, J., van Leuven, F., Edy, V. G., de Ley, M., Cassiman, J. J., van den Berghe, H., de Somer, P.: Human fibroblast interferon for clinical trials: production, partial purification, and characterization. Antimicrob. Agents Chemother.16, 49–55 (1979).
Edy, V. G., Billiau, A., de Somer, P.: Non-appearance of injected fibroblast interferon in the circulation. Lanceti, 451–452 (1978).
Finter, N B.: Dye uptake methods for assessing viral cytopathogenicity and their application to interferon assays. J. gen. Virol.5, 419–427 (1969).
Greenberg, S. B., Harmon, M. W., Couch, R. C.: Exogenous interferon: stability and pharmacokinetics. In:Stringfellow, D. A. (ed.), Interferon and Interferon Inducers, Clinical Applications, 57–87. New York-Basel: Marcel Dekker 1980.
Habif, D. V., Lipton, R., Cantell, K.: Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc. Soc. exp. Biol. Med.149, 287–289 (1975).
Heremans, H., Billiau, A., de Somer, P.: Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy. Infect. Immun. (in press, 1980).
Lucero, M., Magdelenat, H., Billardon, C., Fridman, W. H., Pouillart, P., Cantell, K., Billiau, A., Falcoff, E.: manuscript in preparation.
Paulson, G., Kapp, J. P.: Movement of sodium-22, radioiodinated protein, and tritiated water from the cisterna magna into the cerebrovascular circulation. J. Neurosurgery27, 138–141 (1967).
Vilcek, J., Sulea, I. T., Zerebeckyj, I. L., Yip, Y. K.: Pharmacokinetic properties of human fibroblast and leukocyte interferons in rabbits. J. clin. Microbiol.11, 102–105 (1980).
Stewart II, W. E.: The Interferon System. Wien-New York: Springer 1979.
Author information
Authors and Affiliations
Additional information
With 2 Figures
Rights and permissions
About this article
Cite this article
Billiau, A., Heremans, H., Ververken, D. et al. Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice. Archives of Virology 68, 19–25 (1981). https://doi.org/10.1007/BF01315163
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01315163